Palvella Therapeutics (PVLA) Operating Leases (2019 - 2023)
Historic Operating Leases for Palvella Therapeutics (PVLA) over the last 5 years, with Q3 2023 value amounting to $12.3 million.
- Palvella Therapeutics' Operating Leases rose 62.21% to $12.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $12.3 million, marking a year-over-year increase of 62.21%. This contributed to the annual value of $12.2 million for FY2022, which is 1153.82% down from last year.
- According to the latest figures from Q3 2023, Palvella Therapeutics' Operating Leases is $12.3 million, which was up 62.21% from $12.8 million recorded in Q2 2023.
- Palvella Therapeutics' 5-year Operating Leases high stood at $16.4 million for Q3 2020, and its period low was $12.2 million during Q3 2022.
- Its 5-year average for Operating Leases is $14.4 million, with a median of $14.7 million in 2021.
- Its Operating Leases has fluctuated over the past 5 years, first soared by 289.33% in 2020, then tumbled by 2105.84% in 2022.
- Over the past 5 years, Palvella Therapeutics' Operating Leases (Quarter) stood at $15.5 million in 2019, then rose by 2.89% to $15.9 million in 2020, then dropped by 13.12% to $13.8 million in 2021, then decreased by 11.54% to $12.2 million in 2022, then increased by 0.4% to $12.3 million in 2023.
- Its Operating Leases was $12.3 million in Q3 2023, compared to $12.8 million in Q2 2023 and $13.1 million in Q1 2023.